MA53358A - Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 - Google Patents

Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Info

Publication number: MA53358A
Authority: MA; Morocco
Prior art keywords: hiv; inhibitors; modified triterpenoids; triterpenoids; modified
Prior art date: 2016-02-04

Application number

MA053358A

Other languages

English (en)

Inventor

Jie Chen

Yan Chen

Ira B Dicker

Richard A Hartz

Nicholas A Meanwell

Alicia Regueiro-Ren

Ny Sin

Sing-Yuen Sit

Jacob Swidorski

Brian Lee Venables

Original Assignee

Viiv Healthcare Uk No 5 Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-04

Filing date

2017-02-02

Publication date

2021-07-21

2017-02-02 Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd

2021-07-21 Publication of MA53358A publication Critical patent/MA53358A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

MA053358A 2016-02-04 2017-02-02 Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 MA53358A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662291298P	2016-02-04	2016-02-04

Publications (1)

Publication Number	Publication Date
MA53358A true MA53358A (fr)	2021-07-21

Family

ID=57995251

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA43960A MA43960B1 (fr)	2016-02-04	2017-02-02	Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MA053358A MA53358A (fr)	2016-02-04	2017-02-02	Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA43960A MA43960B1 (fr)	2016-02-04	2017-02-02	Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Country Status (39)

Country	Link
US (4)	US10421774B2 (fr)
EP (2)	EP3411381B1 (fr)
JP (1)	JP6735837B2 (fr)
KR (1)	KR20180105229A (fr)
CN (1)	CN109153700B (fr)
AR (1)	AR107512A1 (fr)
AU (1)	AU2017215529B2 (fr)
BR (1)	BR112018015629B1 (fr)
CA (1)	CA3013417C (fr)
CL (1)	CL2018002084A1 (fr)
CO (1)	CO2018008157A2 (fr)
CR (1)	CR20180387A (fr)
CY (1)	CY1124353T1 (fr)
DK (1)	DK3411381T3 (fr)
DO (1)	DOP2018000174A (fr)
EA (1)	EA036211B1 (fr)
ES (2)	ES2957767T3 (fr)
HK (1)	HK1256866A1 (fr)
HR (1)	HRP20210502T1 (fr)
HU (1)	HUE054337T2 (fr)
IL (1)	IL260741B (fr)
JO (1)	JOP20170029B1 (fr)
LT (1)	LT3411381T (fr)
MA (2)	MA43960B1 (fr)
MD (1)	MD3411381T2 (fr)
MX (1)	MX2018009514A (fr)
PE (1)	PE20181355A1 (fr)
PL (1)	PL3411381T3 (fr)
PT (1)	PT3411381T (fr)
RS (1)	RS61746B1 (fr)
RU (1)	RU2716502C2 (fr)
SG (1)	SG11201806388XA (fr)
SI (1)	SI3411381T1 (fr)
SM (1)	SMT202100210T1 (fr)
TW (1)	TWI719126B (fr)
UA (1)	UA123867C2 (fr)
UY (1)	UY37109A (fr)
WO (1)	WO2017134596A1 (fr)
ZA (1)	ZA201805044B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR107512A1 (es) *	2016-02-04	2018-05-09	VIIV HEALTHCARE UK Nº 5 LTD	Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
PT3784349T (pt) *	2018-04-24	2024-01-22	Viiv Healthcare Uk No 5 Ltd	Compostos com atividade inibidora de maturação do hiv
US20230045509A1 (en)	2019-12-09	2023-02-09	Viiv Healthcare Company	Pharmaceutical compositions comprising cabotegravir
WO2024089216A1 (fr)	2022-10-27	2024-05-02	Syngenta Crop Protection Ag	Nouveaux composés hétéroaryl-carboxamides contenant du soufre

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en)	1995-06-05	1997-10-21	Biotech Research Labs, Inc.	Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en)	2001-02-02	2004-06-10	Tao Wang	Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en)	2002-09-26	2008-04-29	Panacos Pharmaceuticals, Inc.	Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en)	2003-01-20	2003-02-19	Keen Group Ltd	Seating apparatus
US7745625B2 (en)	2004-03-15	2010-06-29	Bristol-Myers Squibb Company	Prodrugs of piperazine and substituted piperidine antiviral agents
CA2560266A1 (fr)	2004-03-17	2005-09-29	Panacos Pharmaceuticals, Inc.	Sels pharmaceutiques de l'acide 3-<i>o</i>-(3',3'-dimethylsuccinyl)betulinique
TW200628161A (en)	2004-11-12	2006-08-16	Panacos Pharmaceuticals Inc	Novel betulin derivatives, preparation thereof and use thereof
US20090105203A1 (en)	2006-10-16	2009-04-23	Myriad Genetics, Incorporated	Compounds for treating viral infections
CA2714049A1 (fr)	2008-02-14	2009-08-20	Virochem Pharma Inc.	Nouveaux derives de 17ss-lupane
US9067966B2 (en)	2009-07-14	2015-06-30	Hetero Research Foundation, Hetero Drugs Ltd.	Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr)	2010-02-09	2012-02-10	Thales Sa	Dispositif d'entrainement pour des joueurs de rugby
PT2576586E (pt)	2010-06-04	2015-10-23	Bristol Myers Squibb Co	Amidas c-28 de derivados de ácido betulínico c-3 modificadas como inibidores de maturação de hiv
WO2011153315A1 (fr)	2010-06-04	2011-12-08	Bristol-Myers Squibb Company	Dérivés d'acide bétulinique modifiés en c-3, utilisés comme inhibiteurs de maturation du vih
DE102010017786A1 (de)	2010-07-07	2012-01-12	Continental Reifen Deutschland Gmbh	Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
SG192144A1 (en)	2011-01-31	2013-08-30	Bristol Myers Squibb Co	C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
ES2552512T3 (es)	2011-01-31	2015-11-30	Bristol-Myers Squibb Company	Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana
IN2014CN04449A (fr) *	2011-12-14	2015-09-04	Glaxosmithkline Llc
US8906889B2 (en) *	2012-02-15	2014-12-09	Bristol-Myers Squibb Company	C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en)	2012-05-07	2014-11-18	Bristol-Myers Squibb Company	C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US8906900B2 (en)	2012-12-21	2014-12-09	Epizyme, Inc.	PRMT5 inhibitors and uses thereof
US9378035B2 (en)	2012-12-28	2016-06-28	Commvault Systems, Inc.	Systems and methods for repurposing virtual machines
EP2953960A1 (fr) *	2013-02-06	2015-12-16	Bristol-Myers Squibb Company	Triterpénoïdes modifiés en c-19 ayant une activité inhibant la maturation du vih
KR20150121712A (ko) *	2013-02-25	2015-10-29	브리스톨-마이어스 스큅 컴퍼니	Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
CN104877015B (zh) *	2014-02-28	2019-02-01	中国人民解放军军事医学科学院毒物药物研究所	一种三萜-多肽缀合物、其药物组合物及用途
UY36070A (es) *	2014-04-11	2015-10-30	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Triterpenoides con actividad inhibidora de la maduración de hiv
MA40886B1 (fr)	2015-02-09	2020-03-31	Hetero Research Foundation	Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
HRP20241334T1 (hr)	2016-02-04	2025-01-03	Takeda Pharmaceutical Company Limited	Supstituirani piperidinski spoj kao agonist oreksina tipa 2 za liječenje narkolepsije
AR107512A1 (es) *	2016-02-04	2018-05-09	VIIV HEALTHCARE UK Nº 5 LTD	Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1

2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/es active IP Right Grant
- 2017-02-02 MX MX2018009514A patent/MX2018009514A/es active IP Right Grant
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/fr active Application Filing
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/fr active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/pl unknown
- 2017-02-02 SM SM20210210T patent/SMT202100210T1/it unknown
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/ja active Active
- 2017-02-02 MA MA43960A patent/MA43960B1/fr unknown
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/es unknown
- 2017-02-02 ES ES21152161T patent/ES2957767T3/es active Active
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/da active
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/hu unknown
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/zh active Active
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 UA UAA201808249A patent/UA123867C2/uk unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/fr active Active
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/pt active IP Right Grant
- 2017-02-02 UY UY0001037109A patent/UY37109A/es not_active Application Discontinuation
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/ro unknown
- 2017-02-02 TW TW106103410A patent/TWI719126B/zh active
- 2017-02-02 SI SI201730647T patent/SI3411381T1/sl unknown
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/ar active
- 2017-02-02 KR KR1020187025343A patent/KR20180105229A/ko not_active Application Discontinuation
- 2017-02-02 ES ES17704093T patent/ES2862325T3/es active Active
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/lt unknown
- 2017-02-02 EA EA201891649A patent/EA036211B1/ru unknown
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/fr active Active
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/ru active
- 2017-02-02 CR CR20180387A patent/CR20180387A/es unknown
- 2017-02-02 MA MA053358A patent/MA53358A/fr unknown
- 2017-02-02 RS RS20210450A patent/RS61746B1/sr unknown
- 2017-02-02 PT PT177040938T patent/PT3411381T/pt unknown
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/es unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/es unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/es unknown
- 2018-12-12 HK HK18115964.0A patent/HK1256866A1/zh unknown
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
2021
- 2021-03-29 HR HRP20210502TT patent/HRP20210502T1/hr unknown
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/el unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US10421774B2 (en)	2019-09-24
CN109153700B (zh)	2021-03-09
SMT202100210T1 (it)	2021-05-07
ES2957767T3 (es)	2024-01-25
UA123867C2 (uk)	2021-06-16
CY1124353T1 (el)	2022-07-22
MX2018009514A (es)	2018-09-05
MA43960B1 (fr)	2021-02-26
CL2018002084A1 (es)	2018-09-21
LT3411381T (lt)	2021-04-26
SG11201806388XA (en)	2018-08-30
PT3411381T (pt)	2021-03-18
CO2018008157A2 (es)	2018-08-21
CA3013417C (fr)	2024-01-02
US20190359647A1 (en)	2019-11-28
BR112018015629B1 (pt)	2023-10-24
JOP20170029B1 (ar)	2021-08-17
TW201739757A (zh)	2017-11-16
CR20180387A (es)	2018-09-20
MD3411381T2 (ro)	2021-07-31
EA201891649A1 (ru)	2019-02-28
DK3411381T3 (da)	2021-04-06
BR112018015629A2 (pt)	2018-12-26
RU2018130181A3 (fr)	2020-03-05
DOP2018000174A (es)	2018-10-31
PL3411381T3 (pl)	2021-09-13
IL260741B (en)	2020-04-30
HRP20210502T1 (hr)	2021-05-14
RS61746B1 (sr)	2021-05-31
JP6735837B2 (ja)	2020-08-05
AU2017215529A1 (en)	2018-08-23
AU2017215529B2 (en)	2019-01-31
PE20181355A1 (es)	2018-08-22
US20230295220A1 (en)	2023-09-21
AR107512A1 (es)	2018-05-09
CN109153700A (zh)	2019-01-04
KR20180105229A (ko)	2018-09-27
RU2018130181A (ru)	2020-03-05
EA036211B1 (ru)	2020-10-14
ZA201805044B (en)	2020-08-26
US20190031709A1 (en)	2019-01-31
RU2716502C2 (ru)	2020-03-12
EP3831839A2 (fr)	2021-06-09
HUE054337T2 (hu)	2021-08-30
US11084845B2 (en)	2021-08-10
EP3411381B1 (fr)	2021-01-20
MA43960A (fr)	2018-12-12
TWI719126B (zh)	2021-02-21
ES2862325T3 (es)	2021-10-07
CA3013417A1 (fr)	2017-08-10
WO2017134596A1 (fr)	2017-08-10
JP2019504104A (ja)	2019-02-14
EP3831839A3 (fr)	2021-07-21
AU2017215529A8 (en)	2018-08-30
EP3831839B1 (fr)	2023-07-26
SI3411381T1 (sl)	2021-04-30
US20210323997A1 (en)	2021-10-21
EP3411381A1 (fr)	2018-12-12
HK1256866A1 (zh)	2019-10-04
UY37109A (es)	2017-09-29

Publication	Publication Date	Title
IL304134A (en)	2023-09-01	Compositions for treating congenital adrenal hyperplasia
BR112017004535A2 (pt)	2018-07-03	esteroides neuroativos, composições e utilizações deste
DK3310389T3 (da)	2020-08-10	Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis
ZA201707303B (en)	2020-01-29	Compositions and methods for the treatment of immunodeficiency
IL267673B1 (en)	2023-03-01	Broadly neutralizing antibodies against hiv-1 and methods of using them
IL269334A (en)	2019-11-28	Improved t cell compositions and methods
PL3598537T3 (pl)	2024-12-16	Sposób wytwarzania mieszaniny elektrodowej oraz mieszanina elektrodowa
IL280082A (en)	2021-03-01	Neuroactive steroid solutions and their methods of use
DK3194564T3 (da)	2020-10-19	Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3589315A4 (fr)	2021-06-23	Compositions et procédés pour induire des anticorps anti-vih-1
EP3650019B8 (fr)	2023-10-11	Furoate de fluticasone utilisé dans le traitement de la bpco
HK1256866A1 (zh)	2019-10-04	作為hiv-1抑制劑之c-3及c-17改質三萜系化合物
HK1256633A1 (zh)	2019-09-27	非晶奧那司酮組合物及其製備方法
LT3463328T (lt)	2022-08-10	Seladelparas pirminiam tulžies cholangitui gydyti
HK1246653A1 (zh)	2018-09-14	奧那司酮延長釋放組合物和方法
DK3018383T3 (da)	2019-06-11	Afslutning af styrkeelementer i dybhavskabler
PL3373922T3 (pl)	2022-05-02	Kompozycje i sposoby do stosowania do leczenia homocystynurii
IL246643A0 (en)	2016-08-31	Preparations and kits for the treatment of immunodeficiency virus/acquired immunodeficiency syndrome
GB201810520D0 (en)	2018-08-15	Branched acid emulsifer compositions and methods of use
IL270823A (en)	2020-01-30	Insulating factors, kits for them, and methods for using insulating factors and kits for them
DK3212800T3 (da)	2021-12-06	21-hydroxylering af steroider
IT201700039351A1 (it)	2018-10-10	Miscela antimeristematica e antigermogliante
MA45387A (fr)	2019-04-24	Compositions comprenant du timolol et un agent anti-inflammatoire
EP3286335A4 (fr)	2018-10-17	Compositions et procédés se rapportant à la caractérisation de réservoirs proviraux
EP3271022A4 (fr)	2018-10-31	Anticorps neutralisant le vih-1 et leurs utilisations